Literature DB >> 23024328

Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring?

Katerina Manika1, Kalliopi Chatzika, Konstantinos Zarogoulidis, Ioannis Kioumis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23024328     DOI： 10.1183/09031936.00202411

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  8 in total

1.  Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.

Authors:  Stephanie Thee; Anthony J Garcia-Prats; Heather R Draper; Helen M McIlleron; Lubbe Wiesner; Sandra Castel; H Simon Schaaf; Anneke C Hesseling
Journal:  Clin Infect Dis       Date:  2014-10-30       Impact factor: 9.079

Review 2.  A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.

Authors:  Anushka Naidoo; Kogieleum Naidoo; Helen McIlleron; Sabiha Essack; Nesri Padayatchi
Journal:  J Clin Pharmacol       Date:  2017-07-24       Impact factor: 3.126

3.  Moxifloxacin retains antimycobacterial activity in the presence of gyrA mutations.

Authors:  Marieta McGrath; Nico C Gey van Pittius; Frederick A Sirgel; Paul D Van Helden; Robin M Warren
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

4.  Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.

Authors:  Anushka Naidoo; Maxwell Chirehwa; Helen McIlleron; Kogieleum Naidoo; Sabiha Essack; Nonhlanhla Yende-Zuma; Eddy Kimba-Phongi; John Adamson; Katya Govender; Nesri Padayatchi; Paolo Denti
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.758

5.  Super-compact treatment with a high dose of moxifloxacin in patients with drug-resistant tuberculosis and its resistance mechanisms.

Authors:  Qingjiang Wang; Chunxiao Zhang; Jinhui Guo; Jian Huang; Xiue Xi; Ligong Zhang; Xiuqin Cui
Journal:  Exp Ther Med       Date:  2015-01-29       Impact factor: 2.447

6.  Determination of plasma concentrations of levofloxacin by high performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania.

Authors:  Andrew Ebers; Suzanne Stroup; Stellah Mpagama; Riziki Kisonga; Isaack Lekule; Jie Liu; Scott Heysell
Journal:  PLoS One       Date:  2017-01-31       Impact factor: 3.240

7.  Pulmonary Targeting of Inhalable Moxifloxacin Microspheres for Effective Management of Tuberculosis.

Authors:  Bhavya Vishwa; Afrasim Moin; D V Gowda; Syed M D Rizvi; Wael A H Hegazy; Amr S Abu Lila; El-Sayed Khafagy; Ahmed N Allam
Journal:  Pharmaceutics       Date:  2021-01-08       Impact factor: 6.321

Review 8.  Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes.

Authors:  Yuhui Xu; Jianan Wu; Sha Liao; Zhaogang Sun
Journal:  Ann Clin Microbiol Antimicrob       Date:  2017-10-03       Impact factor: 3.944
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.